Journal of Immunology Research
Volume 2017 (2017), Article ID 8450496, 5 pages
https://doi.org/10.1155/2017/8450496

Review Article

Early-Life Intestine Microbiota and Lung Health in Children

Giusy Ranucci,¹ Vittoria Buccigrossi,¹ Maiara Brusco de Freitas,² Alfredo Guarino,¹ and Antonietta Giannattasio1,3

¹Department of Translational Medical Science, Section of Pediatrics, University of Naples Federico II, Naples, Italy
²Federal University of Santa Catarina, Florianopolis, SC, Brazil
³Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy

Correspondence should be addressed to Giusy Ranucci; giusyranucci@hotmail.it

Received 5 March 2017; Revised 3 July 2017; Accepted 20 July 2017; Published 21 November 2017

Academic Editor: Mitesh Dwivedi

Copyright © 2017 Giusy Ranucci et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

The gastrointestinal microbiota plays a critical role in nutritional, metabolic, and immune functions in infants and young children and has implications for future lung health status. Understanding the role of intestinal dysbiosis in chronic lung disease progression will provide opportunities to design early interventions to improve the course of the disease. Gut microbiota is established within the first 1 to 3 years of life and remains relatively stable throughout the life span. In this review, we report the recent development in research in gut-lung axis, with focus on the effects of targeting microbiota of infants and children at risk of or with progressive lung diseases. The basic concept is to exploit this approach in critical window to achieve the best results in the control of future health.

1. Introduction

Clinical research in the last decades focused on host-microbe crosstalk especially at intestinal level raising the hypothesis that the gut microbiota is one of the key factors that determine host health. The immune and metabolic functions are influenced by the colonization of intestine by friendly bacteria [1] and a growing number of diseases derive from the gut microbiota composition. The change in microbiota structure often starts in the early life in children with or at risk of chronic diseases, such as cystic fibrosis [2, 3].

The microbiome is established within the first 1 to 3 years of life and remains relatively stable throughout the life span [4]. The neonatal period is a critical window for immune programming that affects the global health status for a lifetime, and the development of the gut microbiota may help predicting specific disease risk and disease progression or elimination of disease altogether [5].

In this review, we analyze the main factors and phases of early microbial imprinting, gut-lung axis in the progression of chronic lung diseases in children, and the manipulation of early-life gut microbiota for modifying history of lung diseases in children.

2. Factors Influencing Gut Microbiota Composition in Early Infancy

Environmental factors together with genetics and immune system activity influence microbial colonization pattern in newborns Table 1. The concept that the fetus is sterile has been reconsidered after detection of microbial traces in fetal and maternal compartments [6, 7]. It is now believed that there is a prenatal colonization with vertically transferred microbial material.

Table 1: Main factors and phases of early microbial imprinting.

(1) Prenatal (colonization with vertically transferred microbial material)

(2) Delivery (cesarean section versus natural)

(3) Feeding (human milk versus formula milk)

(4) Infections

(5) Antibiotics

(6) Intestinal environment (cystic fibrosis, short gut, celiac disease)

The type of delivery influences the pattern of colonization in infant gut. Vaginally delivered infants are colonized with bacterial communities from the mother’s vaginal and intestinal tract. Infants born to cesarean section lack such exposure, leading to the first establishment of bacteria similar to the human skin microbiota [8]. In addition, the intestinal colonization by Lactobacillus, Bifidobacteria, and Bacteroides in infants born by cesarean section is delayed [9].

Infant feeding influences the gut microbial composition with long-lasting effects. Breastfeeding has been associated with a variety of long-term beneficial effects including lower incidence of obesity [10], diabetes [11], and allergies [12, 13]. Breast milk is the gold standard in infant nutrition, because it is species specifically adapted to the infant nutritional needs and functional to drive the development of the immune system. In addition to nutritional support, breast milk provides bioactive constituents that promote the growth of a wide and dynamic array of microorganisms [14]. Colostrum has higher microbial diversity than transitional and mature milk, and factors influencing the microbial community in breast milk also depend on the mother’s nutritional status and the type of delivery.

An infant gut microbiota dominated by Bifidobacteria has consistently been associated with host health. The predominance of Bifidobacteria in breastfed infant stools was firstly found over 100 years ago, suggesting that breast milk contains specific molecules that stimulate the growth of these bacteria, defined as bifidus factors [15]. Today, compelling evidence show that prebiotics in breastmilk promote the growth of Bifidobacteria. The latter dominate the microbiota of breastfed infants, whereas formula-fed infants had higher proportions of Bacteroides and members of the Clostridium coccoides and Lactobacillus groups [16]. In addition, breastfeeding modulates innate immune response [17].

Antibiotics have a major impact on gut microbiome composition particularly in young infants. In the latter, the gut bacteria structure is very unstable, and the continuous and repeated use of antibiotics, especially if the antibiotic used is a broad-spectrum one, profoundly alters gut microbial structure with major late clinical consequences. Recent papers show that prenatal use of antibiotics is associated with an increased risk of subsequent asthma [18].

Of course, antibiotics are often necessary for certain conditions, but their use should be considered in the light of the new data summarized in Table 2. Russell and colleagues found that perinatal antibiotic use exerts highly selective modifications on resident gut flora, which in turn lead to very specific alterations in susceptibility to TH2- or TH1-/TH17-driven lung inflammatory disease [19]. A recent study found that children lacking four bacteria types were more likely to develop asthma, but the only significant environmental factor among these children was receiving more antibiotics in their first year of life than children with lower asthma risk [18]. Early infantile infections including common intestinal infections do change intestinal microbial structure with long-lasting effects [20].

Table 2: Gut microbiota alterations induced by antibiotic use.

Antibiotics
Gut microbiota alterations
Study
References

Ciprofloxacin
Decrease of the taxonomic richness, diversity, and evenness of the community
Healthy adult humans
[41, 42]

Amoxicillin
Cefoperazone
Long-lasting alterations in the gut microbial community including a decrease in overall diversity
Young mice
[43]

Ampicillin
Vancomycin
Metronidazole
Neomycin
Decrease of microbial diversity and colonization with antibiotic-resistant microbes
Young mice
[44]

Ceftriaxone
Gut microbiota dysbiosis
Adult mice
[45]

3. Gut-Lung Axis in the Progression of Chronic Lung Diseases in Children

The gut and respiratory epithelia provide a physical barrier against microbial penetration, and colonization with the normal microbiota generates resistance to pathogens. The role of microbiota in lung homeostasis and immunity is supported by the poor outcomes of germ-free mice that were exposed to acute infections [21] and their susceptibility to allergic airway disease [22]. Dysbiosis in the gut has recently been linked to alterations in immune responses and to disease development in the lungs. In the last few years, chronic lung diseases, such as asthma and cystic fibrosis, have been investigated to evaluate the potential role of intestinal dysbiosis in their development. Primarily, exacerbations of chronic gut and lung diseases share key conceptual features with the dysregulation of intestinal microbial ecosystem.

Cystic fibrosis (CF) is a disease in which recurrent and chronic infection leads to a progressive decline of lung function and ultimately to death. In observational studies in humans, CF has been associated with aberrant microbial colonization of the intestinal and the respiratory tracts. These findings are the likely consequences of the loss of CF transmembrane conductance regulator (CFTR) function and the resulting altered microenvironment [23]. Mutations in CFTR fundamentally affect the airway and intestinal microenvironment and result in abnormal colonization pattern of microorganisms in patients with CF even in the absence of antibiotic exposure [24]. More severe CFTR allelic variants such as homozygous DF508 correlate with more significant alterations in gut microbiome pattern. Chronic gut inflammation is seen in CF even in the absence of overt gastrointestinal symptoms and is thought to be a driver of systemic inflammation, a hallmark of the disease [25]. The association between gut microbial colonization in early life and respiratory outcomes in patients with CF has been investigated, and breastfeeding was associated with delayed exacerbations, gut diversity, and prolonged periods of well-being and specific bacterial communities in the gut prior to respiratory complications [26]. Bacteria in the respiratory tract in CF originate from intestinal microbiota and are thought to contribute to the dynamic interactions between the host and microbial communities in CF [27].

Studies have demonstrated also a relationship between poor nutrition and the development of bronchopulmonary dysplasia in preterm infants who require prolonged supplemental oxygen therapy [28]. No data are available regarding gut dysbiosis in this setting.

Children developing asthma have a reduced gut microbial diversity in the first year of life as compared to healthy children [29]. In particular, delivery mode has been associated with wheezing and asthma until school age, mediated by specific gut bacterial groups [30]. The presence of beneficial bacteria, such as Bifidobacterium longum, and a reduction in Bacteroides fragilis [31] in the gut have been associated with a lower incidence of asthma. The relative abundance of the bacterial genera Lachnospira, Veillonella, Faecalibacterium, and Rothia seems significantly decreased in children at risk of asthma, with consequent reduced levels of fecal acetate and dysregulation of enterohepatic metabolites [31].

4. Manipulation of Early-Life Gut Microbiota in Lung Diseases in Children

Oral administration of probiotics and prebiotics or a combination of both (the so-called “synbiotic approach”) could indirectly influence the composition of airway microbiota through the release of bacterial products or metabolites that reach the lung and promote the outgrowth of beneficial bacteria or directly, via microaspiration of the probiotic strain from the intestinal tract to the airways [32]. These mechanisms may restore a health-promoting microbiota and have a beneficial effect on the course of the disease. Moreover, few probiotic strains have a role in modifying the course of lung diseases. In animal studies, Lactobacilli have profound immunoregulatory effects on the lung, but the results of clinical trials in humans have been highly variable. Strain differences may in part explain the observed variability.

In humans, administration of Lactobacillus GG (LGG) negatively influenced the incidence of ventilator-associated pneumonia [33] and reduced respiratory infections in healthy as well as hospitalized children [34].

Asthma is a major potential target for probiotics, due to its frequency, related pathogenesis, and the lack of consistently effective preventive strategies. However, data on early intestine microbial manipulation are missing, because asthma develops progressively until school age, and the long-term follow-up of probiotic and prebiotic study is limited.

Manipulation of gut microbiota in CF by changing dietary content of indigestible carbohydrate and short-chain fatty acids, namely, butyrate, may improve undernutrition and play an anti-inflammatory effect on animals [35]. Restoration of gut microbiota by probiotics improves nutritional status, energy intake, and respiratory function in cystic fibrosis [35]. Three RCT concluded that probiotic administration in particular LGG and Lactobacillus reuteri has been related with a reduction of episodes of pulmonary exacerbations in children with CF [36–38]. The first evidence of the potential benefits of probiotic administration in CF came from a prospective randomized placebo-controlled crossover trial performed in two groups of patients with CF chronically colonized by Pseudomonas aeruginosa. Nineteen children were given LGG for 6 months followed by placebo (oral rehydration solution) for the subsequent 6 months. In parallel, 19 children were given the placebo during 6 months then the probiotic for the same period of time. The patients on LGG had a significant reduction of intestinal inflammation and of episodes of pulmonary exacerbations and hospitalization rates, with a decrease in IgG, suggesting that there is a relationship between intestinal and pulmonary inflammation. The intake of this probiotic was associated with a significant increase of the maximal forced expiratory volume in 1 second (FEV1) compared to the placebo as well as to a significant increase of body weight [36]. In another prospective randomized, double-blind, placebo-controlled study, 61 patients with CF were randomly assigned to receive 10¹⁰ colony-forming units Lactobacillus reuteri per day or placebo for 6 months. Pulmonary exacerbations and the number of upper respiratory tract infections were significantly reduced in the treatment group compared with the placebo group [39].

As for bronchopulmonary dysplasia, no studies on humans have been conducted with pre- or probiotics. Moreover, in intermittent hypoxia induced in animal models, the supplementation with probiotics may improve pulmonary status, by acting on the specific matrix metalloproteinases suggesting a beneficial effect on lung inflammation. In addition, prebiotic uses have been associated with arrested lung vascular endothelial growth factor signaling highly involved in lung microvascular development, suggesting preservation of angiogenesis [40].

However, the effects of probiotics are likely to be time-dependent, indicating the need for comparative clinical trials evaluating early-life microbiota modulation impact on lung health status. In particular, future studies are required in order to analyze how gut microbial composition in early life influence lung disease occurrence and history, investigating also the role of functional foods in preventing and/or modifying lung health status in children.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This paper has been produced with a grant support by the North American Cystic Fibrosis Foundation (Grant no. GUARIN10A0).

References

C. A. Kerr, D. M. Grice, C. D. Tran et al., “Early life events influence whole-of-life metabolic health via gut microflora and gut permeability,” Critical Reviews in Microbiology, vol. 41, pp. 326–340, 2015.

G. Reid, P. Brigidi, J. P. Burton et al., “Microbes central to human reproduction,” American Journal of Reproductive Immunology, vol. 73, pp. 1–11, 2015.

S. Rautava, R. Luoto, S. Salminen, and E. Isolauri, “Microbial contact during pregnancy, intestinal colonization and human disease,” Nature Reviews. Gastroenterology & Hepatology, vol. 9, pp. 565–576, 2012.

T. Yatsunenko, F. E. Rey, M. J. Manary et al., “Human gut microbiome viewed across age and geography,” Nature, vol. 486, pp. 222–227, 2012.

J. C. Mandan, “Neonatal gastrointestinal and respiratory microbiome in cystic fibrosis: potential interactions and implications for systemic health,” Clinical Therapeutics, vol. 38, pp. 740–746, 2016.

S. Rautava, M. C. Collado, S. Salminen, and E. Isolauri, “Probiotics modulate host-microbe interaction in the placenta and fetal gut: a randomized, double-blind, placebo-controlled trial,” Neonatology, vol. 102, pp. 178–184, 2012.

K. Aagaard, J. Ma, K. M. Antony, R. Ganu, J. Petrosino, and J. Versalovic, “The placenta harbors a unique microbiome,” Science Translational Medicine, vol. 6, pp. 237–265, 2014.

M. G. Dominguez-Bello, E. K. Costello, M. Contreras et al., “Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, pp. 11971–11975, 2010.

I. Adlerberth, E. Lindberg, N. Aberg et al., “Reduced enterobacterial and increased staphylococcal colonization of the infantile bowel: an effect of hygienic lifestyle?” Pediatric Research, vol. 59, pp. 96–101, 2006.

M. Kalliomäki, M. C. Collado, S. Salminen, and E. Isolauri, “Early differences in fecal microbiota composition in children may predict overweight,” The American Journal of Clinical Nutrition, vol. 87, pp. 534–538, 2008.

C. G. Owen, R. M. Martin, P. H. Whincup, G. D. Smith, and D. G. Cook, “Does breastfeeding influence risk of type 2 diabetes in later life? A quantitative analysis of published evidence,” The American Journal of Clinical Nutrition, vol. 84, pp. 1043–1054, 2006.

M. Gdalevich, D. Mimouni, M. David, and M. Mimouni, “Breast-feeding and the onset of atopic dermatitis in childhood: a systematic review and meta-analysis of prospective studies,” Journal of the American Academy of Dermatology, vol. 45, pp. 520–527, 2001.

B. E. Snijders, C. Thijs, P. C. Dagnelie et al., “Breast-feeding duration and infant atopic manifestations, by maternal allergic status, in the first 2 years of life (KOALA study),” The Journal of Pediatrics, vol. 151, pp. 347–351, 2001.

R. Cabrera-Rubio, M. C. Collado, K. Laitinen, S. Salminen, E. Isolauri, and A. Mira, “The human milk microbiome changes over lactation and is shaped by maternal weight and mode of delivery,” The American Journal of Clinical Nutrition, vol. 96, pp. 544–551, 2012.

E. Moro, “Morphologische und biologische Untersuchung über die Darmbakterien des Säuglings,” Jahrbuch für Kinder, vol. 61, pp. 687–734, 1905.

M. Fallani, D. Young, and J. Scott, “Intestinal microbiota of 6-week-old infants across Europe: geographic influence beyond delivery mode, breast-feeding, and antibiotics,” Journal of Pediatric Gastroenterology and Nutrition, vol. 51, pp. 77–84, 2010.

M. E. Belderbos, M. L. Houben, G. M. Bleek et al., “Breastfeeding modulates neonatal innate immune responses: a prospective birth cohort study,” Pediatric Allergy Immunology, vol. 1, pp. 208–222, 2010.

M. C. Arrieta, L. T. Stiemsma, P. A. Dimitriu et al., “Early infancy microbial and metabolic alterations affect risk of childhood asthma,” Science Translational Medicine, vol. 7, p. 307, 2015.

S. L. Russell, M. J. Gold, L. A. Reynolds et al., “Perinatal antibiotic-induced shifts in gut microbiota have differential effects on inflammatory lung diseases,” The Journal of Allergy and Clinical Immunology, vol. 1, pp. 100–109, 2015.

S. M. Karst, “Identification of a novel cellular target and a co-factor for norovirus infection - B cells & commensal bacteria,” Gut Microbes, vol. 4, pp. 266–271, 2015.

C. T. Fagundes, F. A. Amarai, A. T. Vieira et al., “Transient TLR activation restores inflammatory response and ability to control pulmonary bacterial infection in germfree mice,” Journal of Immunology, vol. 188, pp. 1411–1420, 2012.

T. Olszak, D. An, S. Zeissig et al., “Microbial exposure during early life has persistent effects on natural killer T cell function,” Science, vol. 336, pp. 489–493, 2012.

E. F. McKone, S. S. Emerson, K. L. Edwards, and M. L. Aitken, “Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study,” Lancet, vol. 361, pp. 1671–1676, 2003.

M. J. Cox, M. Allgaier, B. Taylor et al., “Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients,” PloS One, vol. 5, p. 11044, 2010.

A. Munck, “Cystic fibrosis: evidence for gut inflammation,” The International Journal of Biochemistry & Cell Biology, vol. 52, pp. 180–183, 2012.

A. G. Hoen, J. Li, and L. A. Moulton, “Associations between gut microbial colonization in early life and respiratory outcomes in cystic fibrosis,” The Journal of Pediatrics, vol. 67, pp. 138–147, 2015.

G. B. Rogers, M. P. Carroll, L. R. Hoffman, A. W. Walker, D. A. Fine, and K. D. Bruce, “Comparing the microbiota of the cystic fibrosis lung and human gut,” Gut Microbes, vol. 1, pp. 85–93, 2010.

M. A. Biniwale and R. A. Ehrenkranz, “The role of nutrition in the prevention and management of bronchopulmonary dysplasia,” Seminars in Perinatology, vol. 30, pp. 200–208, 2006.

T. R. Amsson, H. E. Jakobsson, A. F. Andersson, B. Björkstén, L. Engstrand, and M. C. Jenmalm, “Low gut microbiota diversity in early infancy precedes asthma at school age,” Clinical and Experimental Allergy, vol. 44, pp. 842–850, 2014.

F. A. Nimwegen, J. Pemders, E. E. Stobberingh et al., “Mode and place of delivery, gastrointestinal microbiota, and their influence on asthma and atopy,” The Journal of Allergy and Clinical Immunology, vol. 128, pp. 948–955, 2011.

C. Vael, V. Nelen, S. L. Verhulst, H. Goossens, and K. N. Desager, “Early intestinal Bacteroides fragilis colonisation and development of asthma,” BMC Pulmonary Medicine, vol. 8, p. 19, 2008.

P. Forsythe, “Probiotics and lung diseases,” Chest, vol. 139, pp. 901–908, 2011.

K. Hatakka, E. Savilahti, A. Ponka et al., “Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial,” BMJ, vol. 322, p. 1327, 2001.

I. Hojsak, S. Abdovic, and H. Szajewska, “Lactobacillus GG in the prevention of nosocomial gastrointestinal and respiratory tract infections,” Pediatrics, vol. 125, pp. 1171–1177, 2010.

L. Li and S. Somerset, “The clinical significance of the gut microbiota in cystic fibrosis and the potential for dietary therapies,” Clinical Nutrition, vol. 33, pp. 571–580, 2014.

E. Bruzzese, V. Raia, M. I. Spagnuolo et al., “Effect of Lactobacillus GG supplementation on pulmonary exacerbations in patients with cystic fibrosis: a pilot study,” Clinical Nutrition, vol. 26, pp. 322–328, 2007.

B. Weiss, Y. Bujanover, Y. Yahav, D. Vilozni, E. Fireman, and O. Efrati, “Probiotic supplementation affects pulmonary exacerbations in patients with cystic fibrosis: a pilot study,” Pediatric Pulmonology, vol. 45, pp. 536–540, 2010.

G. Nardo, S. Oliva, A. Menichella et al., “Lactobacillus reuteri ATCC55730 in cystic fibrosis,” Journal of Pediatric Gastroenterology and Nutrition, vol. 58, pp. 81–86, 2010.

A. Ananthan, H. Bakasubramanian, S. Rao, and S. Patole, “Probiotic supplementation in children with cystic fibrosis: a systematic review,” European Journal of Pediatrics, vol. 175, pp. 1255–1266, 2016.

A. Ahmad, C. L. Cai, D. Kumar et al., “Benefits of pre-, pro- and syn-biotics for lung angiogenesis in malnutritional rats exposed to intermittent hypoxia,” American Journal of Translational Research, vol. 6, pp. 459–470, 2014.

L. Dethlefsen, S. Huse, M. L. Sogin, and D. A. Relman, “The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing,” PLoS Biology, vol. 6, no. 11, article e280, 2008.

L. Dethlefsen and D. A. Relman, “Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation,” Proceedings of the National Academy of Sciences, vol. 108, Supplement 1, pp. 4554–4561, 2010.

D. A. Antonopoulos, S. M. Huse, H. G. Morrison, T. M. Schmidt, M. L. Sogin, and V. B. Young, “Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation,” Infection and Immunity, vol. 77, no. 6, pp. 2367–2375, 2009.

C. Ubeda, Y. Taur, R. R. Jenq et al., “Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans,” Journal of Clinical Investigation, vol. 120, no. 12, pp. 4332–4341, 2010.

Y. Guo, X. Yang, Y. Qi et al., “Long-term use of ceftriaxone sodium induced changes in gut microbiota and immune system,” Scientific Reports, vol. 7, article 43035, 2017.